Subacute cutaneous lupus erythematosus lesions precipitated by griseofulvin

Miyagawa, Sachiko; Okuchi, Toshie; Shiomi, Yuko; Sakamoto, Kuniki

doi:10.1016/s0190-9622(89)80031-3

Cited by 67 publications

(20 citation statements)

References 13 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Anti-SSA/Ro-associated drug-induced LE is believed to be an entity distinct from classical drug-induced LE, because the former is characterized primarily by cutaneous disease and lacks antihistone antibodies [5]. The causal drugs for this disease are variable, such as hydrochlorothiazide, calcium channel blockers, angiotensin-converting enzyme inhibitors, griseofulvin and terbinafine [5,7,8,9]. It is well known that FU agents induce DLE-like eruptions in Japan [1].…”

Section: Discussionmentioning

confidence: 99%

Anti-SSA/Ro Antibody as a Risk Factor for Fluorouracil-Induced Drug Eruptions Showing Acral Erythema and Discoid-Lupus-Erythematosus-Like Lesions

Adachi¹,

Nagai²,

Horikawa³

2006

Dermatology

View full text Add to dashboard Cite

Background: It is well known that fluorouracil (FU) agents frequently induce discoid-lupus-erythematosus (DLE)-like eruptions and acral erythema in Japan. However, the etiology of these drug eruptions caused by FU agents has not been clarified yet. Objective: To determine if the existence of anti-SSA/Ro antibody may be a risk factor for FU-agent-induced DLE-like eruptions and acral erythema. Patients and Methods: Six patients with FU-agent-induced drug eruptions showing DLE-like lesions and acral erythema were enrolled in this study. The titers of anti-SSA/Ro antibody in the sera and the histopathology of the skin lesions were examined. Results: Biopsy specimens from DLE-like eruptions and all 5 examined acral erythema cases showed lichenoid change of the basal keratinocytes. Direct immunofluorescence studies revealed deposition of immunoglobulins along the basement membrane zone in the lesions of both DLE-like eruptions and acral erythema. Further, all 6 cases had high titers of serum anti-SSA/Ro antibody, which did not decline within 6 months after cessation of the causative drug. Conclusion: We propose that anti-SSA/Ro antibody may be a risk factor for FU-agent-induced drug eruptions showing acral erythema and DLE-like eruptions.

show abstract

Section: Discussionmentioning

confidence: 99%

Anti-SSA/Ro Antibody as a Risk Factor for Fluorouracil-Induced Drug Eruptions Showing Acral Erythema and Discoid-Lupus-Erythematosus-Like Lesions

Adachi¹,

Nagai²,

Horikawa³

2006

Dermatology

View full text Add to dashboard Cite

show abstract

“…The main other drugs associated with the disease are calcium channel blockers, captopril and sys- 3 Drugs reported in the literature to induce cases of lupus erythematosus Streptomycin, tetracycline, penicillin, oral contraceptives, griseofulvin, calcium channel blockers, captopril, interferon-␣, minocycline, interleukin-2, clonidine, antihistamines, proton pump inhibitors, infl iximab, amiodarone, hypolipemia drugs, para-aminosalicylic acid Table 2. Molecules reported with druginduced SCLE Thiazides [5,37] Nifedipine, verapamil, diltiazem [38] Captopril [39] Terbinafi ne [40,41], griseofulvin [42] D-Penicillamine [43] Piroxicam [43] Naproxen [43] Sulfonylureas [43] Oxprenolol [43] Aldactone [43] Cinnarizine [44] Cilazapril [45] Interferon-␤ [46] Ranitidine [47] Chrysotherapy [43] ( table 2 ). Beta-blocking agents are rarely associated with DILE.…”

Section: Discussionmentioning

confidence: 99%

Acebutolol-Induced Subacute Cutaneous Lupus Erythematosus

Fenniche

Dhaoui

Ammar

et al. 2005

Skin Pharmacol Physiol

View full text Add to dashboard Cite

Beta-blocking medications are rarely associated with drug-induced lupus erythematosus syndrome and have never been incriminated as a cause of subacute lupus erythematosus (SCLE). We present herein the first case of SCLE induced by acebutolol. A 57-year-old woman presented with a 1-month history of a cutaneous eruption of the photoexposed areas. One month ago, the patient had started a treatment with oral acebutolol to cure a hypertension of 1-year evolution. Physical examination revealed erythematous scaly annular plaques, involving the face, arms and trunk. Immunologic serology findings revealed a positive titer of antinuclear antibodies up to 1/1,280 with positivity of antihistone and Ro/SSA antibodies. Acebutolol was stopped, and the lesions cleared completely 4 months later. Literature data, along with our case, suggest a link between acebutolol therapy and the onset of a lupus syndrome. Although this is the first report of acebutolol-induced SCLE, we should be aware of this occurrence, and avoidance of acebutolol is recommended in patients with stigmata of lupus erythematosus

show abstract

“…Lupus erythematosus may flare after sun or UV expo sure and after intake of photosensitizing food or drugs such as antibiotics and NSAIDs, especially the SCLE variant [8][9][10]. In recent years several reports of SCLE precipitated by photoactive drugs have been published [9,10].…”

Section: Discussionmentioning

confidence: 99%

“…In recent years several reports of SCLE precipitated by photoactive drugs have been published [9,10].…”

Section: Discussionmentioning

confidence: 99%

“…Patients with Ro antibodies may have Sjogren's syndrome for many years and then suddenly develop lupus erythematosus and vice versa [2,11], A close relationship between Ro antibody positivity (SSA) and photosensitivity, especially in SCLE, has been reported |2, 111. Furthermore, in patients with Sjogren's syndrome, the use of a potential photosensitizing agent may trigger the first 'diagnostic' flare of lupus erythema tosus [8][9][10], This is the case with our patient, who suffered from Sjogren's syndrome and seronegative polyarthritis. After piroxicam intake, she developed a photosensitivity reac tion with SCLE lesions.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Systemic Lupus erythematosus Exacerbated by Piroxicam

1991

View full text Add to dashboard Cite

A patient with Sjögren’s syndrome and seronegative polyarthritis is reported. After piroxicam intake and sun exposure she developed subacute cutaneous lupus erythematosus lesions with Ro antibodies. Despite drug withdrawal, typical cutaneous lesions and serological markers of systemic lupus erythematosus (SLE) progressively appeared. The use of piroxicam and other nonsteroidal anti-inflammatory drugs with photosensitizing potential in patients with Sjögren’s syndrome, sicca syndrome or a high suspicion of a collagen disorder should be avoided because these drugs may trigger a latent SLE.

show abstract

Subacute cutaneous lupus erythematosus lesions precipitated by griseofulvin

Cited by 67 publications

References 13 publications

Anti-SSA/Ro Antibody as a Risk Factor for Fluorouracil-Induced Drug Eruptions Showing Acral Erythema and Discoid-Lupus-Erythematosus-Like Lesions

Anti-SSA/Ro Antibody as a Risk Factor for Fluorouracil-Induced Drug Eruptions Showing Acral Erythema and Discoid-Lupus-Erythematosus-Like Lesions

Acebutolol-Induced Subacute Cutaneous Lupus Erythematosus

Systemic Lupus erythematosus Exacerbated by Piroxicam

Contact Info

Product

Resources

About